UBS Group
DCGOW

UBS Group’s DocGo Inc. Warrants DCGOW Stock Holding History

UBS Group’s Portfolio DCGOW Stock Details DCGOW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,891
Closed -$9K – 10538
2021
Q2 		$9K Buy
5,891
+5,464
+1,280% +$6K ﹤0.01% 8188
2021
Q1 		$0 Buy
+427
New +$662 ﹤0.01% 9743

Other funds holding DCGOW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
CCM
Cinctive Capital Management New York $1.53B AUM 48.83% 1-Year Est. Return

UBS Group's DCGOW Position: Q3 2021 in Review

UBS Group sold out of DocGo Inc. Warrants (DCGOW) in Q3 2021, closing a stake of 5,891 shares — an estimated $9K sold.

UBS Group first reported a position in DCGOW in Q1 2021 and held it in 2 quarters. The position peaked at $9K in Q2 2021. 12 funds tracked by Wall St. Rank hold DCGOW as of Q3 2021.

  • UBS Group reported no remaining DocGo Inc. Warrants position as of Q3 2021 after selling out during the quarter.
  • UBS Group sold 5,891 DocGo Inc. Warrants shares in Q3 2021, an estimated $9K.
  • UBS Group first reported a position in DocGo Inc. Warrants in Q1 2021 and held it in 2 quarters.
  • UBS Group's DocGo Inc. Warrants position peaked at $9K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held DocGo Inc. Warrants as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.